Patrys (ASX:PAB)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Patrys.
RELATED STOCKHEAD STORIES
Rise and Shine: Everything you need to know before the ASX opens
Biocurious: Sometimes an effective therapy lies not just with the drug, but how it is delivered
Health Check: After an ‘extraordinary’ year, analysts reckon Telix has a lot more tiger in the tank
Health Check: It’s a wipe out! Percheron shares tumble up to 91pc on rare genetic disease trial failure
Health Check: Chinese consumer market is a thing of beauty, says EZZ Life Sciences
Health Check: Farewell, adieu as Argent Biopharma holders back ASX delisting
Rise and Shine: Everything you need to know before the ASX opens
ASX Health Stocks: Patrys and Next Science jump after presenting data on studies
ASX Health Stocks: Patrys to commence Phase 1 trial as drug production process put in motion
In Case You Missed It: Lithium takes the lead, followed by biotech and manganese today
ASX Health Stocks: Patrys, Immutep jump after reports show drugs well tolerated
Top 10 at 10: These ASX lithium, gas and biotech stocks are Hump Day heroes
ASX Health Stocks: Patrys crashes after Phase 1 delayed till 2024, Nova Eye surges 20pc on FDA OK
